BL-8040
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Non-Hodgkin's Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease, Hodgkins Disease, Hodgkin's Disease, Multiple Myeloma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
Trial Timeline
Mar 31, 2016 → Apr 7, 2023
NCT ID
NCT02639559About BL-8040
BL-8040 is a phase 2 stage product being developed by BioLineRx for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02639559. Target conditions include Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02639559 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myelogenous Leukemia